Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Plus Docetaxel and Capecitabine in TNBC
NCT01939054Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Sep 2013
- Primary completion
- Sep 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nimotuzumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate up to 1 year. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01939054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939054.